COMMUNIQUÉS West-GlobeNewswire

Entera Bio Announces First Quarter 2025 Financial Results and Business Updates
09/05/2025
JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for [...]
Oculis Publishes Invitation to the Annual General Meeting
09/05/2025
ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at [...]
Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment
09/05/2025
- Stenoparib continues to demonstrate clinical benefit in heavily pre-treated ovarian cancer, with two patients remaining on treatment for more than 19 months - Initiated utilization of share repurchase program - Cash [...]
Oculis Publishes Invitation to the Annual General Meeting
09/05/2025
ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), today published the invitation to the 2025 Annual General Meeting, which will be held on June 4, 2025 at [...]
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/05/2025
MALVERN, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]
Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update
09/05/2025
SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt [...]
BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025
09/05/2025
SUNNYVALE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it [...]
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/05/2025
CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with [...]
Olema Oncology to Participate in Upcoming Investor Conferences
09/05/2025
SAN FRANCISCO, May 09, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA) a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Publication relative à des notifications de transparence
09/05/2025
INFORMATION RÉGLEMENTÉE Publication relative à des notifications de transparence Mont-Saint-Guibert (Belgique), le 9 mai 2025 , 22:30h CET / 16:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à la [...]
Publication relating to transparency notifications
09/05/2025
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), May 9, 2025 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure [...]
Coave Therapeutics Launches coAAV-CSF-01, a Novel CNS-Targeted Gene Therapy Vector for Neurodegenerative and other CNS Diseases
09/05/2025
New breakthrough data from studies with Coave’s ALIGATER™-engineered AAV2-based capsid coAAV-CSF-01 (S01coAAV2) demonstrates improved brain tissue transduction and safety following intra-cerebrospinal fluid [...]
HealthEquity Announces First Quarter Earnings Release Date Presentations at Investor Conferences
09/05/2025
DRAPER, Utah, May 09, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest health savings account (“HSA") custodian, today announced plans to release its [...]
Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting
09/05/2025
Late-breaking oral presentation to include full 12-month clinical data from INSPIRE registrational Phase 3 trial in addition to topline 18-month and 24-month data from patients prior to open-label extension NEW YORK, [...]
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting
09/05/2025
First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study (IGOS) of the Real-World Evidence (RWE) Results Showing Improved Outcomes with Tanruprubart (formerly ANX005) Compared to Current [...]
Just in Time for Mother's Day: FamilyWell’s Maternal Mental Health Program Now Accessible in Four States
09/05/2025
BOSTON, May 09, 2025 (GLOBE NEWSWIRE) -- Available in Four States — Having already established a strong presence in Massachusetts and New Hampshire, FamilyWell Health is now extending its reach to Texas and Connecticut [...]
LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia
09/05/2025
Exclusive agreement includes up to $125 million in upfront and milestone payments to LENZ together with double-digit royalties on future net sales SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ [...]
Celularity Announces Full Year 2024 Operating and Financial Results
09/05/2025
Net revenues for the year ending December 31, 2024, totaled $54.2 million, an increase of $31.4 million, or 138.1%, compared to the previous year. FLORHAM PARK, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. ( [...]
Vystar Develops Revolutionary Leap in Air Purification Utilizing its Patented Hughes Reactor
09/05/2025
Boston, MA, May 09, 2025 (GLOBE NEWSWIRE) -- Vystar ® Corporation (OTCQB: VYST) Vystar has completed what it believes to be a revolutionary, next-generation RXAIR prototype using the new Fluid Energy Conversion - Hughes [...]

Pages